LeMaitre Vascular Inc (NASDAQ:LMAT) – Barrington Research increased their Q1 2018 earnings per share estimates for LeMaitre Vascular in a research note issued to investors on Thursday, according to Zacks Investment Research. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will post earnings per share of $0.20 for the quarter, up from their prior forecast of $0.19. Barrington Research also issued estimates for LeMaitre Vascular’s Q2 2018 earnings at $0.26 EPS, Q3 2018 earnings at $0.25 EPS and FY2018 earnings at $0.98 EPS.
Several other analysts have also weighed in on LMAT. BidaskClub lowered shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Saturday, December 2nd. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Thursday, December 28th. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $33.00 price objective on shares of LeMaitre Vascular in a report on Friday, February 23rd. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $34.00.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.01. The firm had revenue of $26.15 million during the quarter, compared to analysts’ expectations of $26.23 million. LeMaitre Vascular had a net margin of 17.03% and a return on equity of 16.93%. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.13 earnings per share.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 5th. Stockholders of record on Thursday, March 22nd will be issued a dividend of $0.07 per share. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.06. The ex-dividend date is Wednesday, March 21st. This represents a $0.28 annualized dividend and a dividend yield of 0.76%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 25.88%.
In related news, CEO George W. Lemaitre sold 5,700 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $35.56, for a total value of $202,692.00. Following the completion of the sale, the chief executive officer now owns 3,259,263 shares of the company’s stock, valued at $115,899,392.28. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman George W. Lemaitre sold 45,000 shares of the firm’s stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $34.66, for a total transaction of $1,559,700.00. Following the completion of the sale, the chairman now directly owns 3,225,709 shares of the company’s stock, valued at approximately $111,803,073.94. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 137,736 shares of company stock valued at $4,866,186. Company insiders own 23.70% of the company’s stock.
Several institutional investors have recently modified their holdings of LMAT. Alliancebernstein L.P. acquired a new stake in shares of LeMaitre Vascular in the second quarter valued at approximately $331,000. Teachers Advisors LLC increased its holdings in shares of LeMaitre Vascular by 26.5% in the second quarter. Teachers Advisors LLC now owns 27,724 shares of the medical instruments supplier’s stock valued at $866,000 after purchasing an additional 5,806 shares in the last quarter. Northern Trust Corp grew its holdings in LeMaitre Vascular by 9.8% during the 2nd quarter. Northern Trust Corp now owns 239,671 shares of the medical instruments supplier’s stock worth $7,483,000 after acquiring an additional 21,473 shares during the period. Vanguard Group Inc. grew its holdings in LeMaitre Vascular by 23.5% during the 2nd quarter. Vanguard Group Inc. now owns 815,580 shares of the medical instruments supplier’s stock worth $25,462,000 after acquiring an additional 155,249 shares during the period. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in LeMaitre Vascular during the 2nd quarter worth $137,000. 72.88% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://weekherald.com/2018/03/14/lemaitre-vascular-inc-lmat-to-post-q1-2018-earnings-of-0-20-per-share-barrington-research-forecasts.html.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.